Table of Contents Author Guidelines Submit a Manuscript
International Journal of Medicinal Chemistry
Volume 2014 (2014), Article ID 614808, 18 pages
http://dx.doi.org/10.1155/2014/614808
Review Article

Synthesis and Structural Activity Relationship Study of Antitubercular Carboxamides

1Department of Pure and Industrial Chemistry, University of Nigeria, Nsukka 410002, Nigeria
2Department of Chemical Sciences, Federal University, Wukari, Nigeria

Received 21 August 2014; Revised 21 November 2014; Accepted 30 November 2014; Published 30 December 2014

Academic Editor: Arie Zask

Copyright © 2014 D. I. Ugwu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. 2014, http://en.wikipedia.org/wiki/Tuberculosis.
  2. J. H. Bates and W. W. Stead, “The history of tuberculosis as a global epidemic,” Medical Clinics of North America, vol. 77, no. 6, pp. 1205–1217, 1993. View at Google Scholar · View at Scopus
  3. T. M. Daniel, “The history of tuberculosis,” Respiratory Medicine, vol. 100, no. 11, pp. 1862–1870, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. WHO, “Global tuberculosis control: surveillance, planning and financing,” Tech. Rep., WHO, 2008. View at Google Scholar
  5. M. A. Espinal, “The global situation of MDR-TB,” Tuberculosis, vol. 83, no. 1–3, pp. 44–51, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Johnsson and P. G. Schultz, “Mechanistic studies of the oxidation of isoniazid by the catalase peroxidase from Mycobacterium tuberculosis,” Journal of the American Chemical Society, vol. 116, no. 16, pp. 7425–7426, 1994. View at Google Scholar · View at Scopus
  7. A. Rattan, A. Kalia, and N. Ahmad, “Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives,” Emerging Infectious Diseases, vol. 4, no. 2, pp. 195–209, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Bodmer, K. Zurcher, P. Imboden, and A. Telenti, “Mutation position and type of substitution in the β-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis,” Journal of Antimicrobial Chemotherapy, vol. 35, no. 2, pp. 345–348, 1995. View at Publisher · View at Google Scholar
  9. A. C. Fluit, M. R. Visser, and F.-J. Schmitz, “Molecular detection of antimicrobial resistance,” Clinical Microbiology Reviews, vol. 14, no. 4, pp. 836–871, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Nayyar and R. Jain, “Recent advances in new structural classes of anti-tuberculosis agents,” Current Medicinal Chemistry, vol. 12, no. 16, pp. 1873–1886, 2005. View at Publisher · View at Google Scholar
  11. B. R. Bloom and C. J. L. Murray, “Tuberculosis: commentary on a reemergent killer,” Science, vol. 257, no. 5073, pp. 1055–1064, 1992. View at Publisher · View at Google Scholar · View at Scopus
  12. R. G. Ducati, A. Ruffino-Netto, L. A. Basso, and D. S. Santos, “The resumption of consumption—a review on tuberculosis,” Memorias do Instituto Oswaldo Cruz, vol. 101, no. 7, pp. 697–714, 2006. View at Google Scholar · View at Scopus
  13. R. Loddenkemper, D. Sagebiel, and A. Brendel, “Strategies against multidrug-resistant tuberculosis,” European Respiratory Journal. Supplement, vol. 36, pp. 66s–77s, 2002. View at Google Scholar · View at Scopus
  14. G. di Perri and S. Bonora, “Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?” Journal of Antimicrobial Chemotherapy, vol. 54, no. 3, pp. 593–602, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. W. R. Bishai and R. E. Chaisson, “Short-course chemoprophylaxis for tuberculosis,” Clinics in Chest Medicine, vol. 18, no. 1, pp. 115–122, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. P. G. Smith and A. R. Moss, “Epidemiology of tuberculosis,” in Tuberculosis: Pathogenesis, Protection and Control, B. Bloom, Ed., pp. 47–59, ASM Press, Washington, DC, USA, 1994. View at Google Scholar
  17. P. C. Hopewell, “Overview of clinical tuberculosis,” in Tuberculosis: Pathogenesis, Protection and Control, B. Bloom, Ed., pp. 25–46, ASM Press, Washington, DC, USA, 1994. View at Google Scholar
  18. D. E. Snider Jr., M. Raviglione, and A. Kochi, “Global burden of tuberculosis,” in Tuberculosis: Pathogenesis, Protection, and Control, B. Bloom, Ed., pp. 3–11, ASM Press, Washington, DC, USA, 1994. View at Google Scholar
  19. I. Bastian and R. Colebunders, “Treatment and prevention of multidrug-resistant tuberculosis,” Drugs, vol. 58, no. 4, pp. 633–661, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. T. G. Benedek, “The history of gold therapy for tuberculosis,” Journal of the History of Medicine and Allied Sciences, vol. 59, no. 1, pp. 50–89, 2004. View at Publisher · View at Google Scholar
  21. A. J. Lenaerts, M. A. DeGroote, and I. M. Orme, “Preclinical testing of new drugs for tuberculosis: current challenges,” Trends in Microbiology, vol. 16, no. 2, pp. 48–54, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. European Medicines Agency and Committee for Medicinal Products for Human Use (CHMP), “CHMP assessment report,” Tech. Rep. EMA/CHMP/329898/2013, European Medicines Agency, 2013. View at Google Scholar
  23. http://www.cdc.gov/tb.
  24. 2014, http://www.ema.europa.eu.
  25. D. Sriram, P. Yogeeswari, P. Senthilkumar et al., “Synthesis and antimycobacterial evaluation of novel phthalazin-4-ylacetamides against log- and starved phase cultures: research article,” Chemical Biology and Drug Design, vol. 75, no. 4, pp. 381–391, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Sriram, P. Yogeeswari, P. Senthilkumar, and D. Sangaraju, “5-Nitrothiazolylthiosemicarbazones: synthesis and antimycobacterial evaluation against tubercular and non-tubercular mycobacterial species,” Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 25, no. 1, pp. 105–110, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Sriram, P. Yogeeswari, M. Dinakaran, D. Banerjee, P. Bhat, and S. Gadhwal, “Discovery of novel antitubercular 2,10-dihydro-4aH-chromeno[3,2-c]pyridin-3-yl derivatives,” European Journal of Medicinal Chemistry, vol. 45, no. 1, pp. 120–123, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Indumathi, S. Perumal, D. Banerjee, P. Yogeeswari, and D. Sriram, “l-Proline-catalysed facile green protocol for the synthesis and antimycobacterial evaluation of [1,4]-thiazines,” European Journal of Medicinal Chemistry, vol. 44, no. 12, pp. 4978–4984, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Balamurugan, S. Perumal, A. S. K. Reddy, P. Yogeeswari, and D. Sriram, “A facile domino protocol for the regioselective synthesis and discovery of novel 2-amino-5-arylthieno-[2,3-b]thiophenes as antimycobacterial agents,” Tetrahedron Letters, vol. 50, no. 45, pp. 6191–6195, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. R. R. Kumar, S. Perumal, S. C. Manju, P. Bhatt, P. Yogeeswari, and D. Sriram, “An atom economic synthesis and antitubercular evaluation of novel spiro-cyclohexanones,” Bioorganic and Medicinal Chemistry Letters, vol. 19, no. 13, pp. 3461–3465, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. S. V. Karthikeyan, S. Perumal, K. A. Shetty, P. Yogeeswari, and D. Sriram, “A microwave-assisted facile regioselective Fischer indole synthesis and antitubercular evaluation of novel 2-aryl-3,4-dihydro-2H-thieno[3,2-b]indoles,” Bioorganic and Medicinal Chemistry Letters, vol. 19, no. 11, pp. 3006–3009, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Sriram, P. Yogeeswari, P. Dhakla, P. Senthilkumar, D. Banerjee, and T. H. Manjashetty, “5-Nitrofuran-2-yl derivatives: synthesis and inhibitory activities against growing and dormant mycobacterium species,” Bioorganic and Medicinal Chemistry Letters, vol. 19, no. 4, pp. 1152–1154, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. A. R. Bhat, S. G. Gautham, and K. Mohan, “Synthesis of mannich bases of 7-nitro-2-methyl 4(3H) quinazolinone,” Indian Journal of Heterocyclic Chemistry, vol. 9, pp. 319–320, 2000. View at Google Scholar
  34. C. K. Stover, P. Warrener, D. R. VanDevanter et al., “A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis,” Nature, vol. 405, no. 6789, pp. 962–966, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. W. R. Baker, C. Shaopei, and E. L. Keeler, “Bactericides treating pathogenic infections of mycobacteria, clostridium, cryptosporidium or helicobacter and multidrug-resistant tuberculosis,” US Patent 6,087,358-A, 2000.
  36. R. Pathak, C. S. Pant, A. K. Shaw et al., “Baylis-Hillman reaction: convenient ascending syntheses and biological evaluation of acyclic deoxy monosaccharides as potential antimycobacterial agents,” Bioorganic and Medicinal Chemistry, vol. 10, no. 10, pp. 3187–3196, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. D. G. Rando, D. N. Sato, L. Siqueira et al., “Potential tuberculostatic agents. Topliss application on benzoic acid [(5-Nitro-thiophen-2-yl)-methylene]-hydrazide series,” Bioorganic & Medicinal Chemistry, vol. 10, pp. 557–560, 2002. View at Publisher · View at Google Scholar
  38. T. C. McKee, C. D. Covington, R. W. Fuller et al., “Pyranocoumarins from tropical species of the genus Calophyllum: a chemotaxonomic study of extracts in the National Cancer Institute Collection,” Journal of Natural Products, vol. 61, no. 10, pp. 1252–1256, 1998. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Spino, M. Dodier, and S. Sotheeswaran, “Anti-HIV coumarins from calophyllum seed oil,” Bioorganic and Medicinal Chemistry Letters, vol. 8, no. 24, pp. 3475–3478, 1998. View at Publisher · View at Google Scholar · View at Scopus
  40. A. K. Bakkestuen, L. L. Gundersen, G. Langli, F. Liu, and J. M. Nolsoe, “9-Benzylpurines with inhibitory activity against Mycobacterium tuberculosis,” Bioorganic and Medicinal Chemistry Letters, vol. 10, pp. 1207–1219, 2000. View at Publisher · View at Google Scholar
  41. L. L. Gundersen, J. Nissen-Meyer, and B. Spilsberg, “Synthesis and antimycobacterial activity of 6-arylpurines: the requirements for the N-9 substituent in active antimycobacterial purines,” Journal of Medicinal Chemistry, vol. 45, no. 6, pp. 1383–1386, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Biava, R. Fioravanti, G. C. Porretta, D. Deidda, C. Maullu, and R. Pompei, “New pyrrole derivatives as antimycobacterial agents analogs of BM212,” Bioorganic and Medicinal Chemistry Letters, vol. 9, no. 20, pp. 2983–2988, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Ragno, G. R. Marshall, R. di Santo et al., “Antimycobacterial pyrroles: synthesis, anti-Mycobacterium tuberculosis activity and QSAR studies,” Bioorganic and Medicinal Chemistry, vol. 8, no. 6, pp. 1423–1432, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Waisser, J. Gregor, L. Kubicova et al., “New groups of antimycobacterial agents: 6-chloro-3-phenyl-4-thioxo-2H-1,3-benzoxazine-2(3H)-ones and 6-chloro-3-phenyl-2H-1,3-benzoxazine-2,4(3H)-dithiones,” European Journal of Medicinal Chemistry, vol. 35, pp. 733–741, 2000. View at Publisher · View at Google Scholar
  45. A. Ulubelen, G. Topcu, and C. B. Johansson, “Norditerpenoids and diterpenoids from Salvia multicaulis with antituberculous activity,” Journal of Natural Products, vol. 60, no. 12, pp. 1275–1280, 1997. View at Publisher · View at Google Scholar · View at Scopus
  46. G. A. Wächter, S. G. Franzblau, G. Montenegro et al., “A new antitubercular mulinane diterpenoid from Azorella madreporica clos,” Journal of Natural Products, vol. 61, no. 7, pp. 965–968, 1998. View at Publisher · View at Google Scholar
  47. S. J. Drews, F. Hung, and Y. Av-Gay, “A protein kinase inhibitor as an antimycobacterial agent,” FEMS Microbiology Letters, vol. 205, no. 2, pp. 369–374, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. D. Martin, Z. Jan, C. Carillo et al., “Substituted N-benzylpyrazine-2-carboxamides, their synthesis, hydro-lipophilic properties and evaluation of their antimycobacterial and photosynthesis-inhibiting activity,” in Proceedings of the 15th International Conference on Synthetic Organic Chemistry, 2011.
  49. M. Doležal, J. Zitko, D. Kešetovičová, J. Kuneš, and M. Svobodová, “Substituted N-phenylpyrazine-2-carboxamides: synthesis and antimycobacterial evaluation,” Molecules, vol. 14, no. 10, pp. 4180–4189, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. M. M. Wade and Y. Zhang, “Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosisin vitro,” Journal of Antimicrobial Chemotherapy, vol. 58, no. 5, pp. 936–941, 2006. View at Publisher · View at Google Scholar
  51. TAACF, http://www.taacf.org/Process-text.htm#nhdp-text.
  52. V. Murugan, M. Shukla, K. M. Geetha, A. K. Ashwini, and V. Singh, “Synthesis and biological activities of N-[(2′-Substituted phenyl)-1′, 3′-thiazol-5-one]-naphtho[2,1-b]furan-2-carboxamide derivatives,” Der Pharma Chemica, vol. 3, no. 4, pp. 509–516, 2011. View at Google Scholar · View at Scopus
  53. C. S. M. Lourenco, V. N. M. de Souza, A. C. Pinheiro et al., “Evaluation of anti-tubercular activity of nicotinic and isoniazid analogues,” Arkivoc, no. 15, pp. 181–191, 2007. View at Google Scholar
  54. R. Mannhold, “Medicinal chemistry of DHP-like calcium antagonists,” Drugs of Today, vol. 30, no. 2, pp. 103–122, 1994. View at Google Scholar · View at Scopus
  55. P. S. Eharkar, B. Desai, H. Gaveria et al., “Three-dimensional quantitative structure-activity relationship of 1,4-dihydropyridines as antitubercular agents,” Journal of Medicinal Chemistry, vol. 45, no. 22, pp. 4858–4867, 2002. View at Publisher · View at Google Scholar · View at Scopus
  56. B. Desai, D. Sureja, Y. Nalapara, A. Shah, and A. K. Saxena, “Synthesis and QSAR Studies of 4-Substituted phenyl-2,6-dimethyl-3, 5-bis-N-(substituted phenyl)carbamoyl-1,4-dihydropyridines as potential antitubercular agents,” Bioorganic & Medicinal Chemistry, vol. 9, pp. 1993–1998, 2001. View at Publisher · View at Google Scholar
  57. H. Gaveriya, B. Desai, V. Vora, and A. Shah, “Synthesis and antitubercular activity studies of some unsymmetrical 1,4-dihydropyridines,” Indian Journal of Pharmaceutical Sciences, vol. 64, pp. 59–62, 2002. View at Google Scholar
  58. H. Gaveriya, B. Desai, V. Vora, and A. Shah, “Synthesis of some new unsymmetrical 1,4-dihydropyridine derivatives as potent antitubercular agents,” Heterocyclic Communications, vol. 5, pp. 481–484, 2001. View at Google Scholar
  59. M. Amini, L. Navidpour, and A. Shafiee, “Synthesis and antitubercular activity of new N,N-diaryl-4-(4,5- dichloroimidazole-2-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxamides,” Daru, vol. 16, no. 1, pp. 9–12, 2008. View at Google Scholar · View at Scopus
  60. A. Shafiee, A. R. Dehpour, F. Hadizadeh, and M. Azimi, “Syntheses and calcium channel antagonist activity of nifedipine analogue with methylsulfonylimidazolyl substituent,” Pharmaceutica Acta Helvetiae, vol. 73, no. 2, pp. 75–79, 1998. View at Publisher · View at Google Scholar · View at Scopus
  61. R. J. Clemens and J. A. Hyatt, “Acetoacetylation with 2,2,6-trimethyl-4H-1,3-dioxin-4-one: a convenient alternative to diketene,” The Journal of Organic Chemistry, vol. 50, no. 14, pp. 2431–2435, 1985. View at Publisher · View at Google Scholar
  62. A. Kumar and M. I. Siddiqi, “Recent progress in the development of mycobacterium tuberculosis enoyl acyl carrier protein reductase inhibitors as antitubercular agents,” Biobytes, vol. 4, 2009. View at Google Scholar
  63. M. E. Boyne, T. J. Sullivan, C. W. Ende et al., “Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitors,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 10, pp. 3562–3567, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. S. George and T. K. Ravi, “Design, synthesis and antitubercular screening of certain novel thiadiazolyl pyrrolidine carboxamidesas enoyl acp reductase inhibitors,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 3, no. 4, pp. 280–284, 2011. View at Google Scholar
  65. A. Rosowsky, R. A. Forsch, and S. F. Queener, “Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(ω-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity relative to piritrexim,” Journal of Medicinal Chemistry, vol. 45, no. 1, pp. 233–241, 2002. View at Publisher · View at Google Scholar · View at Scopus
  66. N. Agarwal, P. Srivastava, S. K. Raghuwanshi et al., “Chloropyrimidines as a new class of antimicrobial agents,” Bioorganic and Medicinal Chemistry, vol. 10, no. 4, pp. 869–874, 2002. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Morgan, R. Haritakul, and P. A. Keller, “Anilinopyrimidines as novel antituberculosis agents,” Bioorganic and Medicinal Chemistry Letters, vol. 13, no. 10, pp. 1755–1757, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. V. Vanheusden, H. Munier-Lehmann, M. Froeyen et al., “3′-C-branched-chain-substituted nucleosides and nucleotides as potent inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase,” Journal of Medicinal Chemistry, vol. 46, no. 18, pp. 3811–3821, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. V. Virsodia, R. R. S. Pissurlenkar, D. Manvar et al., “Synthesis, screening for antitubercular activity and 3D-QSAR studies of substituted N-phenyl-6-methyl-2-oxo-4-phenyl-1,2,3,4-tetrahydro-pyrimidine-5-carboxamides,” European Journal of Medicinal Chemistry, vol. 43, no. 10, pp. 2103–2115, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. D. Sriram, P. Yogeeswari, J. T. Patrisha, P. Senthilkumar, P. N. Kurre, and Y. R. Prasad, “Exploring aryl thiazolidine carboxamides as a new class of antimycobacterials,” Pharmacologyonline, vol. 1, pp. 185–195, 2011. View at Google Scholar
  71. T. R. Rawat and S. D. Srivastava, “Synthesis of new benzotriazole derivatives: antimicrobial and anticonvulsant agents,” Indian Journal of Chemistry B, vol. 38, no. 5, pp. 623–627, 1999. View at Google Scholar
  72. A. R. Trivedi, A. B. Siddiqui, and V. H. Shah, “Design, synthesis, characterization and antitubercular activity of some 2-heterocycle-substituted phenothiazines,” Arkivoc, vol. 2008, no. 2, pp. 210–217, 2008. View at Google Scholar · View at Scopus
  73. F. Weng and J. Tan, “Effects of phenothiazine drugs on serum levels of apolipoproteins and lipoproteins in schizophrenic subjects,” Acta Pharmacologica Sinica, vol. 24, no. 10, pp. 1001–1005, 2003. View at Google Scholar
  74. A. Rajasekaran and P. P. Tripathi, “Synthesis and anti-inflammatory activity of some 10-[(1-acyl-1H-tetrazol-5-yl)ethyl]-10H-phenothiazines,” Acta Pharm. Turc., vol. 45, pp. 235–240, 2003. View at Google Scholar
  75. S. Kasmi-Mir, A. Djafri, L. Paquin, J. Hamelin, and M. Rahmouni, “One-pot synthesis of 5-arylidene-2-imino-4-thiazolidinones under microwave irradiation,” Molecules, vol. 11, no. 8, pp. 597–602, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. R. Sharma, P. Samadhiya, S. D. Srivastava, and S. K. Srivastava, “Synthesis and biological activity of 4-thiazolidinone derivatives of phenothiazine,” Journal of the Serbian Chemical Society, vol. 77, no. 1, pp. 17–26, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. K. Pethe, P. C. Sequeira, S. Agarwalla et al., “A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy,” Nature Communications, vol. 1, no. 57, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. J. A. Maddry, S. Ananthan, R. C. Goldman et al., “Antituberculosis activity of the molecular libraries screening center network library,” Tuberculosis, vol. 89, no. 5, pp. 354–363, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. L. Ballell, R. H. Bates, R. J. Young et al., “Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis,” ChemMedChem, vol. 8, no. 2, pp. 313–321, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. E. Alvarez-Ruiz, L. Ballell-Pages, J. Castro-Pichel et al., “Tetrahydropyrazolo [1,5-A] pyrimidine as anti-tuberculosis compounds,” Patent WO2012/143522, 2012.
  81. F. Yokokawa, G. Wang, W. L. Chan et al., “Discovery of tetrahydropyrazolopyrimidine carboxamide derivatives as potent and orally active antitubercular agents,” ACS Medicinal Chemistry Letters, vol. 4, no. 5, pp. 451–455, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. P. Bifani, S. Lakshminarayana, S. Rao et al., “High throughput identification of a novel lethal anti-tubercular Tetrahydropyrazolopyrimidine Carboxamide and its mechanisms of inhibition and resistance,” European Molecular Biology Organization (EMBO). In press.